Costs and Cost Effectiveness of Low Molecular Weight Heparins and Platelet Glycoprotein IIb/IIIa Inhibitors: In the Management of Acute Coronary Syndromes

PharmacoEconomics

Volumn 21, Issue 16, 2003, Pages 1135-1152

  Bosanquet, Nick ^a   Jönsson, Bengt ^b   Fox, Keith A A ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; LOW MOLECULAR WEIGHT HEPARIN; TIROFIBAN;

ACUTE HEART INFARCTION; BLEEDING TENDENCY; BOLUS INJECTION; CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HOSPITAL FINANCE; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; LENGTH OF STAY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE DISEASE; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CLINICAL TRIALS; CORONARY DISEASE; CORONARY RESTENOSIS; COSTS AND COST ANALYSIS; ENOXAPARIN; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MYOCARDIAL INFARCTION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOSIS;

EID: 0345304850     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200321160-00001     Document Type: Review

References (67)

1. Hirsh PD, Hillis LD, Campbell WB, et al. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischaemic heart disease. N Engl J Med 1981; 304: 685-91
2. Hamm CW, Lorenz RL, Bleifeld W, et al. Biochemical evidence of platelet activation in patients with persistent unstable angina. J Am Coll Cardiol 1987; 10: 988-1004
3. Fuster V, Lewis A. Conner Memorial lecture: mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994; 90: 2126-46
4. US Department of Health and Human Services, National Center for Health Statistics. Detailed diagnoses and procedures. In: National Hospital Discharge Survey, 1996. Hyattsville (MD): US Department of Health and Human Services, National Center for Health Statistics, 1998: 13
5. Fox KAA, Goodman SG, Klein W, et al. for the GRACE Investigators. Management of acute coronary syndromes: variations in practice and outcome: findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89
6. Collinson J, Flather MD, Fox KAA, et al. Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK). Eur Heart J 2000; 21: 1450-7
7. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Circulation 2002 Oct 1; 106 (14): 1893-900
8. Théroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-11
9. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827-30
10. Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation 1994; 89: 81-8
11. Oler A, Whooley MA, Oler J, et al. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA 1996; 276: 811-5
12. Hirsh J. Low-molecular-weight heparin: a review of the results of recent studies on the treatment of venous thromboembolism and unstable angina. Circulation 1998; 98: 1575-82
13. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular- weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114 (5 Suppl.): 489S-510S
14. Théroux P, Waters D, Lam J, et al. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992; 327: 141-5
15. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631-7
16. Metz BK, White HD, Granger CB, et al. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. J Am Coll Cardiol 1998; 31: 1493-8
17. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischemia without ST elevation: a randomised trial. Lancet 1999; 353: 429-38
18. Barrowcliffe TW, Johnson EA, Thomas DP. Low molecular weight heparin. Chichester: John Wiley & Sons, 1992
19. Bounameaux H. Low-molecular-weight heparins in prophylaxis and therapy of thromboembolic disease. New York (NY): Marcel Dekker, 1994
20. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-98
21. Bertrand ME, Simoons ML, Fox KAA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2002; 23: 1809-40
22. Lynch Jr JJ, Cook JJ, Sitko GR, et al. Nonpeptide glycoprotein IIb/IIIa inhibitors: 5. antithrombotic effects of MK-0383. J Pharmacol Exp Ther 1995; 272: 20-32
23. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease: Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Group. N Engl J Med 1997; 337: 447-52
24. Antman EM, McCabe CH, Gurfinkel EP, et al., for the TIMI 11B Investigators. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100: 1593-601
25. Antman EM, Cohen M, Radley D, et al., for the TIMI 11B and ESSENCE Investigators. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999; 100: 1602-8
26. Antman EM, Cohen M, McCabe C, et al., for the TIMI 11B and ESSENCE Investigators. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow up of TIMI 11B and ESSENCE. Eur Heart J 2002; 23: 308-14
27. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol 1997; 29: 1474-82
28. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995; 26: 313-8
29. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561-8
30. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular- weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997; 96: 61-8
31. The PRAXIS Study Group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: PRAXIS (FRAXiparine in Ischaemic Syndrome). Eur Heart J 1999; 20: 1553-62
32. Detournay B, Huet X, Fagnani F, et al. Economic evaluation of enoxaparin sodium vs heparin in unstable angina: a French sub-study of the ESSENCE trial. Pharmacoeconomics 2000; 18 (1): 83-9
33. Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment of low molecular weight heparin (enoxaparin) vs unfractionated heparin in acute coronary syndrome patients. Results from the ESSENCE randomized trial. Circulation 1998; 97: 1702-7
34. Fox KAA, Bosanquet N. Assessing the UK cost implications of the use of low molecular weight heparin in unstable coronary artery disease. Br J Cardiol 1998; 5: 95-105
35. Balen RM, Marra CA, Zed PJ, et al. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes: a Canadian hospital perspective. Pharmacoeconomics 1999; 16 (5 Pt 2): 533-42
36. Bozovich G, Gurfinkel E, Barreiro D, et al. Reduction of hospital costs for patients with acute non-Q-wave myocardial infarction or unstable angina treated with enoxaparin compared to standard heparin [abstract]. Eur Heart J 1999; 20: 545
37. Bosanquet N, Fox KAA. Longer-term economic benefits reflect improved clinical outcomes with enoxaparin versus unfractionated heparin in acute coronary syndromes: one-year data. Br J Cardiol 2001; 8: 36-7
38. O'Brien BJ, Willan A, Blackhouse G, et al. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada? Am Heart J 2000; 139: 423-9
39. Harrington RA. Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes. Am Heart J 1999; 138: 276-86
40. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 1998; 97: 2386-95
41. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498-505
42. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488-97
43. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-43
44. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330: 956-61
45. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997; 349: 1429-35
46. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96
47. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade: evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998; 352: 87-92
48. The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001; 357: 1915-24
49. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998; 98: 2829-35
50. Mark DB, Harrington RA, Lincoff AM, et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation 2000; 101: 366-71
51. Henderson RA, Brown R. The costs of routine eptifibatide use in acute coronary syndromes in Western Europe: an economic substudy of the PURSUIT trial. Eur Heart J 1999; Suppl. 1: 35N-41N
52. Mark DB, Talley JD, Topol EJ, et al., for the EPIC Investigators. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. Circulation 1996; 94: 629-35
53. Lincoff AM, Mark DB, Tcheng JE, et al. Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Circulation 2000; 102: 2923-9
54. Weintraub WS, Culler S, Boccuzzi SJ, et al. Economic impact of GPIIb/ IIIa blockade after high-risk angioplasty: results from the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. J Am Coll Cardiol 1999; 34: 1061-6
55. Cohen DJ, O'Shea JC, Pacchiana CM, et al. In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT trial). Am J Cardiol 2002; 89: 61-4
56. Hillegass WB, Newman AR, Raco DL. Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST segment elevation acute coronary syndromes: estimating the economic implications. Pharmacoeconomics 2001; 19: 41-55
57. Brown RE, Henderson RA, Koster D, et al. Cost-effectiveness of eptifibatide in acute coronary syndromes: an economic analysis of Western European patients enrolled in the PURSUIT trial. Eur Heart J 2002; 23: 50-8
58. van Hout BA, Simoons ML. Costs and effects of c7E3 in high risk PTCA patients: an indirect analysis for the Netherlands. Eur Heart J 1995; 16 Suppl. L: 81-5
59. Bowman L, van Hout BA. Cost effectiveness of abciximab at 1 year in the Netherlands [abstract]. Am J Cardiol 1997; 80 Suppl. 7A: 625
60. Bala MV, Anderson KM, Barber BL. Abciximab is cost-effective in patients undergoing percutaneous coronary intervention with stents [abstract]. J Am Coll Cardiol 1999; 33 Suppl. A: 15A
61. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445-53
62. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000; 356: 2037-44
63. Zwart-van Rijkom JEF, Klungel OH, Leufkens HGM, et al. Costs and effects of combining stenting and abciximab (ReoPro®) in daily practice. Int J Cardiol 2001; 77: 299-303
64. Zwart-van Rijkom JEF, van Hout BA. Cost-efficacy in interventional cardiology: results from the EPISTENT study. Eur Heart J 2001; 22: 1476-84
65. Cannon CP, Weintraub WS, Demopoulos LA, et al. for the TACTICS-TIMI 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/ IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879-87
66. Mahoney EM, Cannon CP, Jurkovitz CT, et al. Long-term cost-effectiveness of an early invasive strategy for the treatment of unstable angina and non-ST elevation myocardial infarction. Circulation 2002; 106: II-758, 3722
67. Hamm CW, Heeschen C, Goldmann B, et al., for the CAPTURE Study Investigators. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 1999; 340: 1623-9